Rick Winningham Sells 2,741 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 2,741 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $235.38 on Friday. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $243.32. The stock’s fifty day moving average is $206.99 and its 200 day moving average is $183.17. The stock has a market cap of $14.77 billion, a P/E ratio of -11,763.12, a P/E/G ratio of 0.42 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion for the quarter. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on JAZZ. Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Barclays increased their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday. Wells Fargo & Company increased their price objective on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Finally, Morgan Stanley restated an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $242.65.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals during the second quarter valued at about $127,344,000. Goldentree Asset Management LP bought a new stake in Jazz Pharmaceuticals during the third quarter valued at about $149,597,000. Franklin Resources Inc. raised its holdings in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after acquiring an additional 1,129,995 shares during the period. Bank of New York Mellon Corp raised its holdings in Jazz Pharmaceuticals by 160.2% during the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after acquiring an additional 715,361 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Jazz Pharmaceuticals by 258.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after acquiring an additional 395,000 shares during the period. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.